SecBot SecBot
SECBOTREPLAY Home › Report › PVLA

PVLA · Palvella Therapeutics completed an upsized public offering of 1,840,000…

Palvella Therapeutics Inc. · PRESS-RELEASE filed Mar 2, 2026 at 07:30 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Mar 2, 2026 at 07:30 ET

Palvella Therapeutics completed an upsized public offering of 1,840,000 shares at $125.00 per share, generating $230 million in gross proceeds. The capital will fund development of its QTORIN pipeline, including rapamycin and pitavastatin programs, and support general corporate purposes.

  • Palvella closed a public offering of 1,840,000 shares of common stock at $125.00 per share.
  • The offering included full exercise of the underwriters' option to purchase 240,000 additional shares.
  • Gross proceeds totaled $230 million before underwriting discounts and expenses.
  • Proceeds will be used to advance QTORIN rapamycin and QTORIN pitavastatin programs, and for working capital and R&D.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access